Many men in their 50s have been told to “just accept” lower testosterone as a normal part of aging. Others have heard concerns about prostate cancer or cardiovascular risk that make them hesitant to pursue evaluation, even when symptoms are significant. The result is that a meaningful number of men in their 50s are living with a treatable hormonal deficiency that their physician and their culture have encouraged them to normalize.
This article addresses those concerns with current evidence rather than anecdote. Decisions about testosterone replacement therapy require a more thorough evaluation after 50 — more baseline screening, more specific monitoring, and more careful assessment of the full clinical picture. That is not a reason to avoid treatment. It is a reason to choose a physician-supervised clinic that performs that evaluation correctly.
How Testosterone Levels Typically Look After 50
By the time a man reaches his 50s, he has likely been experiencing gradual testosterone decline for 20 or more years. The 1 to 2 percent annual decline that begins around age 30 compounds over time. For many men, total testosterone in the 50s falls into ranges that are within technical laboratory reference values but below the levels at which their bodies were functioning optimally in earlier adulthood.
Total testosterone values in the 200s to low 300s ng/dL become more common in this age group. But total testosterone does not tell the full story. Sex hormone-binding globulin (SHBG) rises with age, binding testosterone in circulation and reducing the biologically active free testosterone fraction. A man in his 50s can have a total testosterone that appears borderline-normal on a lab report while his free testosterone — the portion that actually reaches receptors in target tissue — is significantly reduced.
This is why evaluation must include free testosterone and SHBG, not just total testosterone. For context on interpreting these lab values by age, see our guide to TRT for men in their 40s which covers the reference ranges and the shift that occurs with age. Clinical diagnosis after 50 still requires both low lab values and corresponding symptoms — age alone does not qualify or disqualify a patient.
Symptoms That Often Drive Men in Their 50s to Seek Evaluation
The symptom profile that prompts men in their 50s to seek evaluation is often more complex than in younger patients, because symptoms have typically been present longer and may have become more pronounced. Common presentations include persistent fatigue that is unresponsive to sleep improvements or lifestyle changes; significant changes in libido and sexual function; loss of lean muscle mass despite maintained exercise; cognitive changes including difficulty concentrating and word recall; mood changes such as increased irritability, low motivation, and depressive symptoms; and weight gain concentrated in the abdomen that resists dietary change.
Men over 50 face a specific diagnostic challenge: many of these symptoms overlap with other conditions that are also more common in this age group. Cardiovascular issues, sleep apnea, thyroid dysfunction, depression, and the metabolic effects of type 2 diabetes can all produce a similar picture. Dr. Jaqua evaluates the full clinical picture at consultation — not just testosterone levels. For detailed information on how labs are interpreted in context, see our reference guide to lab reference values for testosterone by age.
TRT is appropriate only after other contributing causes have been considered. This is not an obstacle to treatment — it is the clinical rigor that makes treatment safe and effective. Treating testosterone deficiency in a patient who also has untreated sleep apnea, for example, without addressing the sleep apnea, produces suboptimal outcomes for both conditions.
Additional Screening That Matters After 50
The baseline evaluation before starting TRT is more thorough for patients over 50, reflecting both the additional health conditions that are more prevalent in this age group and the greater monitoring requirements of older patients on testosterone therapy.
PSA (prostate-specific antigen) is established before starting TRT and monitored at regular intervals. Men over 50 are typically already in the PSA surveillance age range recommended by major guidelines, regardless of TRT. A baseline PSA before starting treatment is essential for any subsequent surveillance to be meaningful.
Digital rectal exam is recommended by many clinical guidelines before initiating TRT in men over 50. Bailey should verify with Dr. Jaqua whether this is standard practice at Vitality Texas for this age group.
Hematocrit and complete blood count are drawn at baseline and all follow-up intervals. Polycythemia risk — the tendency of testosterone to stimulate red blood cell production — is higher in older patients, making this monitoring more consequential than in younger men.
Cardiovascular panel includes lipid panel, blood pressure review, and electrocardiogram if clinically indicated. This is particularly important for patients with existing cardiovascular risk factors or disease history.
Sleep apnea screening is appropriate for patients who describe symptoms consistent with obstructive sleep apnea — heavy snoring, daytime sleepiness, witnessed breathing pauses. Untreated sleep apnea can suppress testosterone independently and can worsen with TRT. Addressing it before or alongside TRT produces better outcomes.
Metabolic panel including glucose and HbA1c provides context on insulin resistance. Type 2 diabetes is associated with secondary hypogonadism through multiple pathways; addressing insulin resistance may partly normalize testosterone independently in some patients.
TRT Monitoring Protocols for Older Patients
Monitoring is more active for patients over 50 than for younger patients, reflecting the greater clinical complexity of this age group. The standard protocol at Vitality Texas includes labs at six to eight weeks after starting treatment — reviewing total testosterone, free testosterone, hematocrit, PSA, and estradiol — with dose adjustment based on both lab results and symptom response.
Ongoing monitoring for stable patients occurs every six to twelve months. Patients whose hematocrit is trending upward may be monitored more frequently until stability is established. A hematocrit above 54 percent requires dose reduction or therapeutic phlebotomy — this threshold is the standard of care.
PSA surveillance follows American Urological Association guidance. A PSA rise of more than 1.4 ng/mL from baseline in the first year, or more than 0.4 ng/mL in any subsequent 12-month period, warrants urology referral. Bailey should verify these specific thresholds with Dr. Jaqua to confirm they reflect Vitality's current practice protocol.
What the Research Shows About TRT After 50
The research base on TRT in older men is substantial. Two landmark studies are directly relevant to men considering TRT after 50.
The Testosterone Trials — a series of coordinated clinical trials published by Snyder et al. in the New England Journal of Medicine in 2016 — enrolled men aged 65 and older with confirmed low testosterone and evaluated the effects of testosterone therapy on multiple outcome domains. The trials found improvements in sexual function, physical function, and bone mineral density in men who received testosterone therapy compared to placebo. This was physician-supervised treatment of confirmed hypogonadism in men significantly older than most of those asking about TRT in their 50s.
The TRAVERSE trial, published by Lincoff et al. in the New England Journal of Medicine in 2023, is the largest randomized controlled trial evaluating cardiovascular safety of testosterone therapy conducted to date. It enrolled 5,246 hypogonadal men with pre-existing cardiovascular disease — a population with significantly elevated baseline cardiovascular risk. The trial found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE), meaning there was no increased risk of heart attack, stroke, or cardiovascular death in the testosterone group compared to placebo in this high-risk population. All patients at Vitality Texas receive cardiovascular baseline evaluation before starting treatment.
Is TRT Safe After 50?
The three concerns most commonly raised about TRT after 50 deserve direct, evidence-based responses.
Prostate cancer risk:Current research does not establish a causal link between testosterone replacement therapy and prostate cancer. The historical concern stems from early observations in the 1940s that androgen deprivation reduced prostate cancer progression — an observation that was extrapolated to suggest that testosterone fuels prostate cancer. The saturation model (Morgentaler & Traish, 2009) provides a more current framework: prostate cells respond to testosterone up to a saturation point, above which additional testosterone does not proportionally stimulate prostate growth. Active or suspected prostate cancer remains a contraindication to TRT. PSA surveillance is mandatory and is performed at Vitality Texas throughout treatment.
Cardiovascular risk: The TRAVERSE trial (2023) found no increased risk of major adverse cardiovascular events in hypogonadal men with pre-existing cardiovascular disease who received testosterone therapy. This does not mean TRT is appropriate for every patient regardless of cardiovascular history — individual risk assessment and baseline evaluation are required. The accurate framing of the TRAVERSE findings is that testosterone was non-inferior to placebo for MACE in hypogonadal men with pre-existing cardiovascular disease. All patients at Vitality Texas receive cardiovascular baseline evaluation before starting treatment.
Polycythemia: Testosterone therapy can raise hematocrit by stimulating red blood cell production. In some patients over 50, this requires dose adjustment or periodic therapeutic phlebotomy. It is a manageable, monitored effect — not a reason to avoid treatment. Routine lab monitoring at Vitality Texas catches hematocrit elevation before it becomes a clinical problem, allowing dose adjustment before the threshold of concern is reached.
Frequently Asked Questions
Does TRT cause prostate cancer?
Current research does not establish a causal link between testosterone replacement therapy and prostate cancer. The historic concern — based on observations in the 1940s — has been reconsidered in light of the saturation model (Morgentaler & Traish, 2009), which suggests prostate cells become saturated with testosterone at relatively low levels and do not respond proportionally to higher concentrations. Active or suspected prostate cancer is a contraindication to TRT. All patients at Vitality Texas receive PSA monitoring before starting and at regular follow-up intervals throughout treatment. Any clinically significant PSA change prompts urology referral. Individual risk assessment occurs at the initial consultation.
Should I be more concerned about cardiovascular risk from TRT after 50?
The TRAVERSE trial (2023) — a large randomized controlled trial of 5,246 hypogonadal men with pre-existing cardiovascular disease — found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE). This does not mean TRT is risk-free for every patient; cardiovascular risk factors, medical history, and individual clinical assessment all matter. At Vitality Texas, all patients receive a cardiovascular baseline evaluation before starting treatment. Ongoing monitoring includes lipid panel review and blood pressure tracking throughout treatment.
Can I start TRT for the first time at 55?
Yes, if labs confirm hypogonadism and symptoms are consistent with testosterone deficiency. Age 55 is not a barrier to starting TRT — many men begin treatment in their 50s, 60s, and beyond after years of normalizing treatable symptoms as inevitable aging. The evaluation process at Vitality Texas includes a free initial consultation, on-site labs with next-day results, and a physician review of your full clinical picture before any treatment begins. Starting later in life does not fundamentally change the protocol, though monitoring may be more frequent initially given the additional screening points relevant to older patients.
References
- Snyder PJ, et al. “Effects of Testosterone Treatment in Older Men.” N Engl J Med. 2016;374(7):611–624.
- Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” N Engl J Med. 2023 (TRAVERSE Trial).
- Morgentaler A, Traish AM. “Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.” European Urology. 2009.
- Bhasin S, et al. “Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2010.